share_log

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20

HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20

HC Wainwright & Co.维持对Entrada Therapeutics的买入,将目标价下调至20美元
Benzinga ·  2023/11/27 07:26

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $25 to $20.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱维持Entrada Therapeutics(纳斯达克股票代码:TRDA)的买入,并将目标股价从25美元下调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发